Search results for: Determining Value

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

1 December 2016

Published paper using MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to assess the value of obinutuzumab for rituximab-refractory iNHL….

New Seminar Briefing: Is Pharmaceutical R&D Experiencing a Productivity Crisis?

14 June 2012

…of these global companies is highest. With respect to sales, “the market value of NMEs for European companies is far lower than the market value for US companies even after…

Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool

9 September 2024

…the development of innovations by evaluating them at their developmental stages, scan and streamline the innovation process by identifying health needs and gaps and estimate and maximise their value early…

Spotlight on OHE: Development and Use of Measures of Health Worldwide

16 July 2012

…Netherlands, and the United States – and plans for EQ-5D-5L Value Sets studies in 2012 and beyond. At ISPOR, Nancy also presented two poster sessions that examined the EQ-5D’s use…

Around the World in HTAs: Kenya – Riding the Waves of Change

19 May 2025

…(2023)), and initiatives like the recently launched social health insurance scheme (SHI) aimed to provide accessible, affordable and quality health services to the population. The value of HTA is enshrined…

Measuring and Valuing Outcomes

…Seven reflections on the UK EQ-5D-5L value set – and what comes next The long-awaited UK EQ-5D-5L value set has been published, marking a key moment for health technology assessment….

Willingness to Pay and Publicly Funded Health Care: Contradiction in Terms?

1 November 2011

Because health care resources always are scarce, decisions about what (and what not) to pay for cannot be avoided. Deciding how to value health and aspects of health care continue…

Lunchtime Seminar: Capturing Preferences about Treatment at the End of Life

9 April 2013

…has been available that either supports or refutes the premise that society places special value on life-extending treatments at the end of life. Future studies of society’s preference about such…

Exploring the Link Between Health and Wealth in Government Decision Making

16 May 2013

Traditionally, decision makers both within and outside the health sector have thought of the value of health interventions primarily in terms of reduced morbidity or mortality. Health care, however, produces…